Compare LTRX & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LTRX | ADAG |
|---|---|---|
| Founded | 1989 | 2011 |
| Country | United States | China |
| Employees | 352 | N/A |
| Industry | Computer Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 236.4M | 260.3M |
| IPO Year | 2000 | 2020 |
| Metric | LTRX | ADAG |
|---|---|---|
| Price | $6.10 | $3.64 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $6.50 | ★ $8.25 |
| AVG Volume (30 Days) | ★ 721.9K | 253.5K |
| Earning Date | 05-06-2026 | 04-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $122,923,000.00 | N/A |
| Revenue This Year | $1.12 | N/A |
| Revenue Next Year | $15.27 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.86 | $1.44 |
| 52 Week High | $8.75 | $4.85 |
| Indicator | LTRX | ADAG |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 47.57 |
| Support Level | N/A | $3.23 |
| Resistance Level | N/A | $3.99 |
| Average True Range (ATR) | 0.00 | 0.28 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 0.00 | 54.76 |
Lantronix Inc is a networking company. It provides secure data access and management solutions for the Internet of Things (IoT) and information technology assets. It organizes its products and solutions into three product lines: Embedded IoT Solutions, IoT Systems Solutions, and Software and Services. The IoT System Solutions segment is the key revenue driver for the company. The company serves a diverse range of markets including healthcare, industrial, security, energy, transportation, and government networking. Its primary geographic markets are the Americas, Europe, the Middle East and Africa, and Asia Pacific Japan. The Americas contribute the vast majority of total revenue.
Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.